Gallimed Sciences, Inc.
Welcome
The conceptual aspect of our invention is quite simple. We have
discovered a pharmaceutical that prevents conception. This is
accomplished via specific (but reversible) inhibition of sperm receptor
expression in the ovary. Without a 'sperm receptor' on the egg,
there is no place for sperm to bind. Fertilization never takes
place. The drug is an orally-administered, non-hormonal molecule
(currently called RovaStat or, formulated for human use, OvaNil) with
little or no toxicity. Further, the molecule is metabolized by
the body into inert or insoluble components -- meaning it cannot
pollute the environment.
Our first product, RovaStat, will involve a humane approach to rodent control. But, there are other pests that contribute heavily to economic losses in the United States. Feral pigs, cats and dogs have become particularly prominent over the last 10 years. By including RovaStat-treated baits as a pest-control strategy for these animals (especially feral pigs, which tend to be seasonal breeders), we can contribute to the reduction in standing populations of these animals.
Currently, spaying and neutering of pet animals (e.g., dogs and cats) is a common method of pet population control. However, spaying is permanent and of highly variable cost. Further, all animal owners (especially breeders) do not want to permanently sterlize their animals – but, rather, control when their females will have litters. In these cases, RovaStat can be incorporated into a pet-food product, and provide adequate, reversible contraception for female pets. Since RovaStat is soluble in DMSO – an alternative delivery system, similar to flea/tick control systems (an organic solution applied intrascapularly beneath the fur) is a viable alternative.
Creating
Value
Nationally, over $19 billion dollars was spent or lost in the U.S. due to the rat population.
The FAO and WHO estimate that India lost 65 million metric tonnes of grain due to rodent damage.
Controlling rodent population growth by only 33% would result in 32 MILLION additional metric tons of grain in India (a value of over $32 Billion)
The worldwide hormonal contraceptive market is over $7 billion and growing at a rate of 10-13%.
It is estimated that an additional $1 billion of market was lost due to women for whom hormonal contraceptives were contraindicated.